Telix Pharmaceuticals (TLX) Retained Earnings (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Retained Earnings for 3 consecutive years, with -$154.5 million the latest figure, recorded in Q4 2025.

• Quarterly Retained Earnings fell 2.75% year-over-year to -$154.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$154.5 million (down 2.75% YoY) and the FY2025 annual result came in at -$154.5 million, down 1.06% from the prior year.
• Retained Earnings eased to -$154.5 million in Q4 2025 per TLX's latest filing, from -$150.4 million in the prior quarter.
• Over the last five years, Retained Earnings for TLX reached as high as -$150.4 million in Q4 2024 and fell as low as -$186.2 million in Q4 2023.
• A 3-year average of -$163.7 million and a median of -$154.5 million in 2025 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2024 — Retained Earnings climbed 19.23% — and 2025, when it slipped 2.75%.
• Year by year, Retained Earnings stood at -$186.2 million in 2023, then advanced by 19.23% to -$150.4 million in 2024, then decreased by 2.75% to -$154.5 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$154.5 million, -$150.4 million, and -$186.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.